Vall d'Hebron Institute of Oncology (VHIO)
José Antonio Seoane has extensive work experience in the field of oncology and bioinformatics. José Antonio is currently working as a Principal Investigator at Vall d'Hebron Institute of Oncology (VHIO) since May 2021. Prior to this, they served as an Instructor and Postdoctoral Research Fellow at Stanford University from 2014 to 2021. José Antonio also worked as a Postdoctoral Research Associate at the University of Southern California in 2014. José Antonio started their career as a Research Assistant in Bioinformatics at the University of Bristol in 2012. Additionally, they have held various R&D Project Contracts and the position of Isabel Barreto Contract Technologist at the University of A Coruña from 2004 to 2011. José Antonio was also associated with the Red Galega de Bioinformática from 2007 to 2009.
José Antonio Seoane earned a Bachelor of Science degree in Computer Engineering from Universidade da Coruña in 2004. José Antonio then pursued a Master of Science degree in Computer Science from the same institution from 2004 to 2008. Following that, they obtained a Doctor of Philosophy (PhD) in Computer Science from Universidade da Coruña between 2008 and 2012. In addition to their academic achievements, José Antonio Seoane also received a certification in EMBO Training: Laboratory Leadership Course from EMBO Solutions GmbH in 2023.
Vall d'Hebron Institute of Oncology (VHIO)
Under the leadership of Josep Tabernero, the Vall d’Hebron Institute of Oncology (VHIO) has established itself as a cancer research center of proven excellence internationally. It is thanks to Josep's directorship and VHIO's optimal organizational structure based on a purely multidisciplinary and translational model that VHIO talents continue to anticipate and tackle the many unresolved questions in combatting this multifaceted and heterogeneous disease. Located within the Vall d´Hebron Barcelona Hospital Campus, our researchers closely collaborate and interact with Vall d´Hebron University Hospital physician-scientists. Translational science and clinical research are therefore tightly connected which promotes superb interaction and teamwork which, in turn, accelerates the bench-bedside-bed cycle of knowledge. This privileged environment affords VHIO direct access to patients as well as the entire spectrum of oncology professionals who care for them, and a second-to-none appreciation of how cancer science can translate into more powerful, targeted treatments and better practice for the care of patients. VHIO's pioneering model and programs, coupled with its belief in combining strengths through cross-border collaborations, continue to spur advances in reversing cancer resistance, halting metastatic spread and more effectively treating even the most undruggable tumour types. VHIO's translation toward precision oncology.